Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Fourth-Quarter 2021 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces New Chief Business Innovation Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer to Acquire Trillium Therapeutics Inc.
From Pfizer Inc.
Via Business Wire
Tickers PFE
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Prices $1.0 Billion Sustainability Bond
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
From Pfizer Inc.
Via Business Wire
Tickers PFE
PFIZER REPORTS SECOND-QUARTER 2021 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Announces New Investor Relations Leader
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.